Background and Rationale

The combined pre‑conditioning regimen of busulfan, etoposide, and total body irradiation (TBI) suppresses both malignant and immune cells, thereby enhancing transplant engraftment rates. This approach seeks to address the toxicity concerns and graft‑versus‑host disease (GVHD) risk associated with conventional conditioning regimens.

Clinical Design and Objectives

Phase II, COMPLETED, sponsored by City of Hope Medical Center. The primary objectives are to characterize treatment safety (adverse events) and determine the optimal dosing schedule, as well as to explore efficacy endpoints such as post‑transplant survival and complete remission rates. The study population comprises patients with progressive hematologic malignancies undergoing hematopoietic stem cell or bone marrow transplantation.

Differentiation from Standard of Care

Traditional conditioning combines busulfan with cyclophosphamide or fludarabine plus TBI. This trial replaces cyclophosphamide with etoposide to diversify DNA replication inhibition mechanisms and improve the toxicity profile. Etoposide is a topoisomerase II inhibitor that promotes tumor cell apoptosis while exhibiting relatively low cardiotoxicity.

Industry and Market Impact

If the conditional conditioning regimen proves safe and efficacious, it could redefine the standard of care in hematopoietic stem cell transplantation. This would expand revenue opportunities for manufacturers of busulfan and etoposide and stimulate development of novel combination products. Additionally, strategies that reduce post‑transplant immune rejection may improve patient quality of life and lower healthcare costs.